Cargando…
Sequential treatment of progressive multifocal leukoencephalopathy with intravenous immunoglobulins and pembrolizumab
Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease of the CNS caused by the human polyomavirus 2 (JCV). PML predominantly occurs in immunocompromised patients. To date, no specific antiviral treatment exists, leaving only restoration of the immune system as possible tre...
Autores principales: | Boesl, Fabian, Allers, Kristina, Herm, Juliane, Scheider, Thomas, Franke, Christiana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187551/ https://www.ncbi.nlm.nih.gov/pubmed/35320511 http://dx.doi.org/10.1007/s13365-022-01059-2 |
Ejemplares similares
-
Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy
por: Mahler, Christoph, et al.
Publicado: (2020) -
Single-Dose Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy
por: Beudel, Martijn, et al.
Publicado: (2021) -
PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy
por: Möhn, Nora, et al.
Publicado: (2021) -
Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency
por: Küpper, Clemens, et al.
Publicado: (2019) -
Use of Pembrolizumab for Treatment of Progressive Multifocal Leukoencephalopathy in People Living with HIV
por: Pinnetti, Carmela, et al.
Publicado: (2022)